| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Marijuana Abuse | 31 | 2021 | 251 | 7.950 |
Why?
|
| Cocaine-Related Disorders | 27 | 2020 | 504 | 3.530 |
Why?
|
| Stress, Psychological | 17 | 2022 | 824 | 2.520 |
Why?
|
| Buspirone | 6 | 2016 | 36 | 2.380 |
Why?
|
| Hydrocortisone | 17 | 2022 | 291 | 2.240 |
Why?
|
| Cannabis | 11 | 2022 | 115 | 1.980 |
Why?
|
| Double-Blind Method | 32 | 2021 | 1738 | 1.880 |
Why?
|
| Cues | 25 | 2022 | 654 | 1.820 |
Why?
|
| Substance-Related Disorders | 13 | 2022 | 1242 | 1.690 |
Why?
|
| Sex Characteristics | 11 | 2020 | 295 | 1.660 |
Why?
|
| Oxytocin | 4 | 2020 | 124 | 1.630 |
Why?
|
| Opioid-Related Disorders | 5 | 2023 | 298 | 1.480 |
Why?
|
| Marijuana Smoking | 10 | 2021 | 108 | 1.470 |
Why?
|
| Progesterone | 4 | 2020 | 115 | 1.370 |
Why?
|
| Cannabinoids | 7 | 2018 | 90 | 1.340 |
Why?
|
| Cocaine | 9 | 2022 | 555 | 1.270 |
Why?
|
| Acetylcysteine | 8 | 2019 | 296 | 1.260 |
Why?
|
| Adult | 74 | 2022 | 21403 | 1.190 |
Why?
|
| Serotonin Receptor Agonists | 3 | 2016 | 34 | 1.150 |
Why?
|
| Craving | 7 | 2022 | 200 | 1.120 |
Why?
|
| Female | 81 | 2022 | 38074 | 1.100 |
Why?
|
| Humans | 99 | 2023 | 68618 | 1.030 |
Why?
|
| Yohimbine | 4 | 2019 | 41 | 1.000 |
Why?
|
| Male | 76 | 2022 | 37321 | 1.000 |
Why?
|
| Substance Withdrawal Syndrome | 6 | 2019 | 435 | 1.000 |
Why?
|
| Self Report | 7 | 2021 | 371 | 0.990 |
Why?
|
| Young Adult | 27 | 2022 | 5717 | 0.930 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2022 | 91 | 0.890 |
Why?
|
| Anxiety | 5 | 2017 | 422 | 0.840 |
Why?
|
| Treatment Outcome | 21 | 2021 | 7029 | 0.840 |
Why?
|
| Corticotropin-Releasing Hormone | 5 | 2017 | 79 | 0.810 |
Why?
|
| Anti-Anxiety Agents | 3 | 2009 | 107 | 0.800 |
Why?
|
| Amphetamine-Related Disorders | 6 | 2012 | 92 | 0.790 |
Why?
|
| Marijuana Use | 2 | 2020 | 35 | 0.770 |
Why?
|
| Medical Marijuana | 2 | 2018 | 21 | 0.760 |
Why?
|
| Parenting | 2 | 2019 | 91 | 0.740 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 3 | 2018 | 189 | 0.740 |
Why?
|
| Pituitary-Adrenal System | 10 | 2022 | 138 | 0.730 |
Why?
|
| Adrenergic alpha-2 Receptor Antagonists | 2 | 2017 | 15 | 0.720 |
Why?
|
| Mothers | 2 | 2019 | 172 | 0.710 |
Why?
|
| Sleep Wake Disorders | 1 | 2021 | 94 | 0.710 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2020 | 52 | 0.700 |
Why?
|
| Adrenocorticotropic Hormone | 10 | 2011 | 106 | 0.690 |
Why?
|
| Ovary | 1 | 2020 | 99 | 0.690 |
Why?
|
| Motivational Interviewing | 2 | 2017 | 40 | 0.680 |
Why?
|
| Hypothalamo-Hypophyseal System | 9 | 2022 | 150 | 0.650 |
Why?
|
| Motivation | 12 | 2020 | 561 | 0.640 |
Why?
|
| Analgesics, Opioid | 3 | 2023 | 498 | 0.640 |
Why?
|
| Drug-Seeking Behavior | 3 | 2017 | 213 | 0.630 |
Why?
|
| Legislation, Drug | 1 | 2018 | 9 | 0.630 |
Why?
|
| Behavior, Addictive | 7 | 2013 | 317 | 0.630 |
Why?
|
| HIV Antibodies | 1 | 2018 | 28 | 0.610 |
Why?
|
| Adolescent | 29 | 2022 | 8912 | 0.610 |
Why?
|
| Psychotherapy | 3 | 2016 | 253 | 0.610 |
Why?
|
| CD4 Antigens | 1 | 2018 | 42 | 0.610 |
Why?
|
| Middle Aged | 41 | 2020 | 21147 | 0.600 |
Why?
|
| Medication Adherence | 4 | 2019 | 335 | 0.590 |
Why?
|
| Public Health | 2 | 2018 | 201 | 0.590 |
Why?
|
| Brain | 6 | 2021 | 2176 | 0.570 |
Why?
|
| Pilot Projects | 8 | 2021 | 1342 | 0.540 |
Why?
|
| Anti-HIV Agents | 1 | 2018 | 135 | 0.540 |
Why?
|
| Norepinephrine | 1 | 2017 | 276 | 0.540 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2018 | 226 | 0.540 |
Why?
|
| Vilazodone Hydrochloride | 1 | 2015 | 6 | 0.530 |
Why?
|
| Placebos | 5 | 2019 | 195 | 0.520 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2016 | 60 | 0.520 |
Why?
|
| Riboflavin | 1 | 2015 | 15 | 0.510 |
Why?
|
| Amines | 1 | 2016 | 98 | 0.510 |
Why?
|
| Saliva | 4 | 2022 | 142 | 0.510 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 481 | 0.500 |
Why?
|
| Dronabinol | 5 | 2019 | 84 | 0.490 |
Why?
|
| Guanfacine | 1 | 2014 | 6 | 0.490 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 1 | 2014 | 11 | 0.490 |
Why?
|
| Smoking Cessation | 2 | 2021 | 1034 | 0.480 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2016 | 208 | 0.470 |
Why?
|
| Alcoholism | 7 | 2019 | 1109 | 0.470 |
Why?
|
| Stress Disorders, Post-Traumatic | 8 | 2013 | 1506 | 0.460 |
Why?
|
| Attitude to Health | 1 | 2016 | 403 | 0.430 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2017 | 413 | 0.430 |
Why?
|
| Cold Temperature | 4 | 2006 | 90 | 0.420 |
Why?
|
| Sertraline | 2 | 2004 | 62 | 0.420 |
Why?
|
| Cycloserine | 4 | 2015 | 30 | 0.410 |
Why?
|
| Sex Factors | 8 | 2022 | 1266 | 0.390 |
Why?
|
| Comorbidity | 7 | 2021 | 1426 | 0.380 |
Why?
|
| Sleep | 3 | 2022 | 263 | 0.370 |
Why?
|
| Propylamines | 1 | 2010 | 22 | 0.370 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2010 | 20 | 0.370 |
Why?
|
| Quality of Life | 2 | 2023 | 1515 | 0.370 |
Why?
|
| Combined Modality Therapy | 4 | 2017 | 951 | 0.360 |
Why?
|
| Antidepressive Agents | 2 | 2002 | 216 | 0.360 |
Why?
|
| HIV Infections | 1 | 2018 | 791 | 0.350 |
Why?
|
| Central Nervous System Stimulants | 3 | 2011 | 221 | 0.340 |
Why?
|
| Affect | 3 | 2015 | 218 | 0.340 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2017 | 468 | 0.340 |
Why?
|
| Methylphenidate | 1 | 2010 | 97 | 0.330 |
Why?
|
| Research Design | 4 | 2019 | 729 | 0.320 |
Why?
|
| Depression | 5 | 2019 | 943 | 0.310 |
Why?
|
| Cross-Over Studies | 5 | 2017 | 260 | 0.290 |
Why?
|
| Recurrence | 6 | 2022 | 948 | 0.280 |
Why?
|
| Anxiety Disorders | 3 | 2006 | 426 | 0.280 |
Why?
|
| Drug Therapy | 1 | 2006 | 71 | 0.270 |
Why?
|
| Heart Rate | 7 | 2015 | 568 | 0.270 |
Why?
|
| Extinction, Psychological | 4 | 2015 | 240 | 0.260 |
Why?
|
| Life Change Events | 4 | 2013 | 223 | 0.260 |
Why?
|
| Surveys and Questionnaires | 7 | 2022 | 2800 | 0.250 |
Why?
|
| Impulsive Behavior | 3 | 2016 | 85 | 0.240 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 931 | 0.230 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2004 | 54 | 0.230 |
Why?
|
| Triazoles | 1 | 2004 | 43 | 0.230 |
Why?
|
| Psychological Tests | 3 | 2013 | 96 | 0.230 |
Why?
|
| Substance Abuse Detection | 3 | 2018 | 66 | 0.220 |
Why?
|
| Varenicline | 2 | 2021 | 98 | 0.210 |
Why?
|
| Clinical Trials as Topic | 3 | 2023 | 848 | 0.210 |
Why?
|
| Biomarkers | 3 | 2018 | 1593 | 0.210 |
Why?
|
| Administration, Intranasal | 2 | 2020 | 88 | 0.210 |
Why?
|
| Citalopram | 1 | 2002 | 30 | 0.210 |
Why?
|
| Hallucinogens | 1 | 2022 | 14 | 0.210 |
Why?
|
| Buprenorphine | 1 | 2023 | 67 | 0.200 |
Why?
|
| Behavior Therapy | 2 | 2018 | 297 | 0.200 |
Why?
|
| Aged | 7 | 2020 | 14862 | 0.200 |
Why?
|
| Estradiol | 2 | 2020 | 176 | 0.200 |
Why?
|
| Arousal | 4 | 2015 | 168 | 0.190 |
Why?
|
| Stress, Physiological | 3 | 2008 | 215 | 0.190 |
Why?
|
| Social Behavior | 2 | 2015 | 164 | 0.190 |
Why?
|
| Nutrition Disorders | 1 | 2000 | 16 | 0.180 |
Why?
|
| Outpatients | 1 | 2021 | 127 | 0.180 |
Why?
|
| Smoking | 5 | 2014 | 1452 | 0.180 |
Why?
|
| Psychiatric Status Rating Scales | 7 | 2011 | 782 | 0.180 |
Why?
|
| Bacteria | 1 | 2021 | 193 | 0.180 |
Why?
|
| Amyloid beta-Peptides | 1 | 2021 | 191 | 0.180 |
Why?
|
| Patient Outcome Assessment | 1 | 2020 | 42 | 0.180 |
Why?
|
| Methamphetamine | 3 | 2010 | 132 | 0.170 |
Why?
|
| Alcohol Deterrents | 1 | 2019 | 86 | 0.160 |
Why?
|
| Nicotine | 1 | 2022 | 350 | 0.160 |
Why?
|
| False Negative Reactions | 1 | 2019 | 63 | 0.160 |
Why?
|
| Feasibility Studies | 2 | 2019 | 652 | 0.160 |
Why?
|
| Personality Inventory | 4 | 2012 | 197 | 0.160 |
Why?
|
| Cognition Disorders | 2 | 2012 | 342 | 0.160 |
Why?
|
| Adaptation, Psychological | 3 | 2018 | 447 | 0.160 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2018 | 17 | 0.150 |
Why?
|
| Macrophages | 1 | 2021 | 647 | 0.150 |
Why?
|
| Inpatients | 1 | 2019 | 208 | 0.150 |
Why?
|
| United States | 5 | 2022 | 7367 | 0.150 |
Why?
|
| Proof of Concept Study | 1 | 2018 | 38 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2014 | 2223 | 0.150 |
Why?
|
| Dietary Supplements | 1 | 2000 | 332 | 0.150 |
Why?
|
| Parent-Child Relations | 1 | 2018 | 98 | 0.150 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2018 | 98 | 0.150 |
Why?
|
| Health Services Research | 1 | 2019 | 209 | 0.150 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2018 | 73 | 0.150 |
Why?
|
| Intraocular Pressure | 1 | 2017 | 143 | 0.150 |
Why?
|
| Social Environment | 2 | 2010 | 182 | 0.140 |
Why?
|
| Oxytocics | 1 | 2017 | 14 | 0.140 |
Why?
|
| Cognition | 3 | 2020 | 513 | 0.140 |
Why?
|
| Dehydroepiandrosterone | 2 | 2014 | 29 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2020 | 310 | 0.140 |
Why?
|
| Behavioral Research | 1 | 2016 | 10 | 0.130 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 1 | 2015 | 11 | 0.130 |
Why?
|
| Menstrual Cycle | 1 | 2016 | 64 | 0.130 |
Why?
|
| Cannabidiol | 1 | 2015 | 31 | 0.130 |
Why?
|
| Adult Survivors of Child Abuse | 1 | 2015 | 20 | 0.130 |
Why?
|
| Child Abuse | 4 | 2013 | 186 | 0.130 |
Why?
|
| Case-Control Studies | 4 | 2021 | 1553 | 0.130 |
Why?
|
| Piperazines | 2 | 2008 | 206 | 0.120 |
Why?
|
| Memory | 2 | 2013 | 214 | 0.120 |
Why?
|
| Alleles | 1 | 2015 | 386 | 0.120 |
Why?
|
| Pain | 1 | 2017 | 472 | 0.120 |
Why?
|
| Age of Onset | 3 | 2012 | 188 | 0.120 |
Why?
|
| Attention | 1 | 2016 | 225 | 0.120 |
Why?
|
| Age Factors | 6 | 2020 | 1864 | 0.110 |
Why?
|
| Nasal Sprays | 1 | 2013 | 11 | 0.110 |
Why?
|
| Free Radical Scavengers | 3 | 2019 | 112 | 0.110 |
Why?
|
| Antimetabolites | 1 | 2013 | 17 | 0.110 |
Why?
|
| Psychomotor Performance | 3 | 2013 | 213 | 0.110 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 2 | 2010 | 151 | 0.110 |
Why?
|
| Implosive Therapy | 1 | 2015 | 171 | 0.110 |
Why?
|
| Propranolol | 1 | 2013 | 103 | 0.110 |
Why?
|
| Patient Compliance | 1 | 2015 | 402 | 0.110 |
Why?
|
| Functional Neuroimaging | 1 | 2013 | 82 | 0.110 |
Why?
|
| Quinoxalines | 1 | 2013 | 78 | 0.110 |
Why?
|
| Follow-Up Studies | 5 | 2013 | 3259 | 0.100 |
Why?
|
| Benzazepines | 1 | 2013 | 104 | 0.100 |
Why?
|
| Health Behavior | 1 | 2016 | 458 | 0.100 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2012 | 128 | 0.100 |
Why?
|
| Affective Symptoms | 1 | 2012 | 50 | 0.100 |
Why?
|
| Naltrexone | 2 | 2019 | 195 | 0.100 |
Why?
|
| Prefrontal Cortex | 1 | 2017 | 640 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2016 | 581 | 0.100 |
Why?
|
| Neurotic Disorders | 1 | 2011 | 13 | 0.100 |
Why?
|
| Photic Stimulation | 4 | 2013 | 229 | 0.090 |
Why?
|
| Analysis of Variance | 3 | 2013 | 1040 | 0.090 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2010 | 14 | 0.090 |
Why?
|
| Fear | 1 | 2012 | 239 | 0.090 |
Why?
|
| Administration, Cutaneous | 1 | 2010 | 56 | 0.090 |
Why?
|
| Association Learning | 1 | 2010 | 36 | 0.090 |
Why?
|
| Cross-Sectional Studies | 5 | 2020 | 2279 | 0.090 |
Why?
|
| Psychotic Disorders | 1 | 2011 | 157 | 0.090 |
Why?
|
| Sample Size | 1 | 2009 | 79 | 0.080 |
Why?
|
| Time Factors | 4 | 2014 | 4655 | 0.080 |
Why?
|
| Hypertriglyceridemia | 1 | 2008 | 21 | 0.080 |
Why?
|
| Cytokines | 1 | 2013 | 866 | 0.080 |
Why?
|
| Depressive Disorder, Major | 1 | 2013 | 439 | 0.080 |
Why?
|
| Mental Disorders | 2 | 2017 | 659 | 0.080 |
Why?
|
| Tobacco Use Disorder | 1 | 2013 | 432 | 0.080 |
Why?
|
| Rural Population | 1 | 2011 | 398 | 0.080 |
Why?
|
| Triglycerides | 1 | 2008 | 184 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 2077 | 0.080 |
Why?
|
| Quinolones | 1 | 2008 | 60 | 0.080 |
Why?
|
| Psychology, Child | 1 | 2007 | 28 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2015 | 411 | 0.070 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2006 | 19 | 0.070 |
Why?
|
| Touch | 1 | 2006 | 25 | 0.070 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2009 | 266 | 0.070 |
Why?
|
| Visual Perception | 1 | 2007 | 124 | 0.070 |
Why?
|
| Crack Cocaine | 1 | 2006 | 20 | 0.070 |
Why?
|
| Antipsychotic Agents | 1 | 2008 | 247 | 0.070 |
Why?
|
| Secondary Prevention | 1 | 2007 | 291 | 0.070 |
Why?
|
| Child | 5 | 2021 | 6405 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 1465 | 0.060 |
Why?
|
| Narcotic Antagonists | 1 | 2006 | 184 | 0.060 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 3 | 2013 | 257 | 0.060 |
Why?
|
| Animals | 2 | 2021 | 20881 | 0.060 |
Why?
|
| Contraindications | 1 | 2002 | 52 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2002 | 26 | 0.050 |
Why?
|
| Cannabinoid Receptor Agonists | 1 | 2022 | 20 | 0.050 |
Why?
|
| Opiate Substitution Treatment | 1 | 2023 | 57 | 0.050 |
Why?
|
| Prospective Studies | 4 | 2013 | 3705 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2002 | 58 | 0.050 |
Why?
|
| Actigraphy | 1 | 2022 | 28 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2002 | 84 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2008 | 1451 | 0.050 |
Why?
|
| Environment | 1 | 2022 | 115 | 0.050 |
Why?
|
| Clonidine | 1 | 2021 | 66 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2008 | 1753 | 0.050 |
Why?
|
| DNA, Ribosomal | 1 | 2021 | 59 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2021 | 85 | 0.050 |
Why?
|
| Neurobiology | 1 | 2001 | 9 | 0.050 |
Why?
|
| Hospitalization | 1 | 2007 | 978 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2002 | 420 | 0.050 |
Why?
|
| Alcohol Drinking | 1 | 2007 | 805 | 0.050 |
Why?
|
| Patient Selection | 2 | 2019 | 592 | 0.050 |
Why?
|
| DNA, Bacterial | 1 | 2021 | 150 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2021 | 208 | 0.050 |
Why?
|
| Phylogeny | 1 | 2021 | 197 | 0.050 |
Why?
|
| Emergency Treatment | 1 | 2001 | 52 | 0.050 |
Why?
|
| Linear Models | 2 | 2013 | 521 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2001 | 289 | 0.050 |
Why?
|
| Brain Mapping | 2 | 2014 | 532 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2000 | 123 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2021 | 174 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2001 | 135 | 0.040 |
Why?
|
| Disulfiram | 1 | 2019 | 22 | 0.040 |
Why?
|
| Neuropsychological Tests | 2 | 2012 | 517 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 131 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2001 | 383 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 955 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 352 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2019 | 307 | 0.040 |
Why?
|
| Cell Line | 1 | 2021 | 1752 | 0.040 |
Why?
|
| Sulpiride | 1 | 2017 | 20 | 0.040 |
Why?
|
| Help-Seeking Behavior | 1 | 2017 | 13 | 0.040 |
Why?
|
| Patient Care Management | 1 | 2017 | 40 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2001 | 1330 | 0.030 |
Why?
|
| Luteinizing Hormone | 1 | 2016 | 31 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2001 | 703 | 0.030 |
Why?
|
| Mass Screening | 1 | 2001 | 843 | 0.030 |
Why?
|
| National Institute on Drug Abuse (U.S.) | 1 | 2014 | 19 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 1603 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 216 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 622 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 2550 | 0.030 |
Why?
|
| Self Administration | 1 | 2015 | 419 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2014 | 159 | 0.030 |
Why?
|
| Prevalence | 2 | 2008 | 1619 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 237 | 0.030 |
Why?
|
| Physical Examination | 1 | 2013 | 152 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 180 | 0.030 |
Why?
|
| Nicotinic Agonists | 1 | 2013 | 111 | 0.030 |
Why?
|
| Individuality | 1 | 2012 | 44 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2013 | 189 | 0.030 |
Why?
|
| Veterans | 1 | 2019 | 904 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 2013 | 156 | 0.020 |
Why?
|
| Reaction Time | 1 | 2012 | 170 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 329 | 0.020 |
Why?
|
| Oxygen | 1 | 2013 | 386 | 0.020 |
Why?
|
| Learning | 1 | 2013 | 186 | 0.020 |
Why?
|
| Neural Pathways | 1 | 2013 | 324 | 0.020 |
Why?
|
| Motor Skills | 1 | 2011 | 88 | 0.020 |
Why?
|
| Prescription Drugs | 1 | 2011 | 71 | 0.020 |
Why?
|
| Educational Status | 1 | 2011 | 273 | 0.020 |
Why?
|
| Personality | 1 | 2011 | 66 | 0.020 |
Why?
|
| Aggression | 1 | 2011 | 98 | 0.020 |
Why?
|
| Demography | 1 | 2011 | 279 | 0.020 |
Why?
|
| Employment | 1 | 2011 | 154 | 0.020 |
Why?
|
| Counseling | 1 | 2012 | 280 | 0.020 |
Why?
|
| Emotions | 1 | 2011 | 244 | 0.020 |
Why?
|
| Galvanic Skin Response | 1 | 2010 | 67 | 0.020 |
Why?
|
| Neurosecretory Systems | 1 | 2009 | 21 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2012 | 340 | 0.020 |
Why?
|
| Mice | 1 | 2021 | 8474 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1054 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 689 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 334 | 0.020 |
Why?
|
| Aripiprazole | 1 | 2008 | 43 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 536 | 0.020 |
Why?
|
| Control Groups | 1 | 2007 | 10 | 0.020 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2007 | 19 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 714 | 0.020 |
Why?
|
| Weight Gain | 1 | 2008 | 135 | 0.020 |
Why?
|
| Risk | 1 | 2009 | 563 | 0.020 |
Why?
|
| Probability | 1 | 2007 | 245 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2019 | 7277 | 0.020 |
Why?
|
| Age Distribution | 1 | 2007 | 320 | 0.020 |
Why?
|
| Immersion | 1 | 2006 | 10 | 0.020 |
Why?
|
| Pituitary Gland | 1 | 2006 | 29 | 0.020 |
Why?
|
| Adrenal Glands | 1 | 2006 | 46 | 0.020 |
Why?
|
| Thermosensing | 1 | 2006 | 10 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 1420 | 0.020 |
Why?
|
| Hypothalamus | 1 | 2006 | 78 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2006 | 107 | 0.020 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2006 | 71 | 0.020 |
Why?
|
| Survivors | 1 | 2007 | 256 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2006 | 218 | 0.020 |
Why?
|
| Reference Values | 1 | 2006 | 579 | 0.020 |
Why?
|
| South Carolina | 1 | 2011 | 2752 | 0.020 |
Why?
|
| Risk Factors | 1 | 2012 | 5731 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 1851 | 0.010 |
Why?
|